BioCardia (BCDA) CEO Peter Altman granted 110,625 fully vested RSUs

Rhea-AI Filing Summary

Altman Peter reported acquisition or exercise transactions in this Form 4 filing.

BioCardia, Inc. reported that President and CEO Peter Altman received an equity compensation award in the form of restricted stock units. He was granted 110,625 shares of common stock at a reference value of $1.20 per share, bringing his direct holdings to 411,191 shares after the award. According to the footnote, these RSUs were granted as compensation in lieu of cash, and 100% of the units vested on June 29, 2026, providing him with an immediate fully vested equity stake.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Altman Peter

Role President and CEO

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	110,625	$1.20	$133K

Holdings After Transaction: Common Stock — 411,191 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

RSU grant size: 110,625 shares Grant value per share: $1.20 per share Post-transaction holdings: 411,191 shares +1 more

4 metrics

RSU grant size 110,625 shares Restricted stock units awarded as compensation in lieu of cash

Grant value per share $1.20 per share Reference price for the RSU award reported in Form 4

Post-transaction holdings 411,191 shares Total common shares directly held by CEO after the grant

Vesting date June 29, 2026 100% of RSUs vested on this date

Key Terms

restricted stock units, compensation in lieu of cash, grant, award, or other acquisition, Form 4

4 terms

restricted stock units financial

"The reported securities represent restricted stock units ("RSUs"), each of which represents a contingent right to receive one share"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

compensation in lieu of cash financial

"RSUs ... awarded as compensation in lieu of cash. 100% of the RSUs vested on June 29, 2026"

grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition" for the CEO’s RSU grant"

Form 4 regulatory

"INSIDER FILING DATA (Form 4): details the CEO’s restricted stock unit grant and resulting holdings"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/01/2026 - 07:38 PM Accepted by SEC EDGAR 07/01/2026 - 07:37 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Altman Peter

(Last) (First) (Middle)

C/O BIOCARDIA, INC.

320 SOQUEL WAY

(Street)

SUNNYVALE CALIFORNIA 94085

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BioCardia, Inc. [ BCDA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/29/2026		A		110,625(1)	A	$1.2(1)	411,191	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported securities represent restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock awarded as compensation in lieu of cash. 100% of the RSUs vested on June 29, 2026.

	/s/ David McClung, by power of attorney	07/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did BioCardia (BCDA) CEO Peter Altman report in this Form 4?

Peter Altman reported receiving 110,625 restricted stock units of BioCardia common stock as compensation in lieu of cash. The award is a non-cash equity grant, fully vested on June 29, 2026, and increases his direct share ownership.

How many BioCardia (BCDA) shares does the CEO hold after this RSU grant?

After the reported grant, Peter Altman directly holds 411,191 shares of BioCardia common stock. This figure includes the 110,625 shares underlying the restricted stock units granted as compensation reported in this Form 4 filing.

Was the BioCardia (BCDA) CEO’s Form 4 transaction an open-market purchase or sale?

The transaction was not an open-market trade. It was a grant of 110,625 restricted stock units awarded as compensation in lieu of cash, coded as an acquisition (A) rather than a market purchase or sale of BioCardia shares.

At what price were the BioCardia (BCDA) RSUs granted to the CEO?

The restricted stock units were valued at $1.20 per share for reporting purposes. This price reflects the reference value used in the Form 4 filing and does not represent an open-market transaction price paid by the CEO.

When did the BioCardia (BCDA) CEO’s restricted stock units vest?

According to the footnote, 100% of the restricted stock units vested on June 29, 2026. This means the entire 110,625-share award became fully vested on that date, subject to the terms of BioCardia’s equity compensation arrangements.